Advanced search
Publication Cover
Autoimmunity Volume 38, 2005 - Issue 7
Submit an article Journal homepage
133
Views
21
CrossRef citations to date
0
Altmetric
Original

Positive and negative effects of thalidomide on refractory cutaneous lupus erythematosus

C. Briani University of Padova, Department of Neurosciences, Via Giustiniani, 5, 35128, Padova, Italy
,
G. Zara University of Padova, Department of Neurosciences, Via Giustiniani, 5, 35128, Padova, Italy
,
R. Rondinone University of Padova, Department of Medical and Surgical Sciences, Rheumatology Division, Padova, Italy
,
L. Iaccarino University of Padova, Department of Medical and Surgical Sciences, Rheumatology Division, Padova, Italy
,
S. Ruggero University of Padova, Department of Neurosciences, Via Giustiniani, 5, 35128, Padova, Italy
,
E. Toffanin University of Padova, Department of Neurosciences, Via Giustiniani, 5, 35128, Padova, Italy
,
M. Ermani University of Padova, Department of Neurosciences, Via Giustiniani, 5, 35128, Padova, Italy
,
A. Ghirardello University of Padova, Department of Medical and Surgical Sciences, Rheumatology Division, Padova, Italy
,
S. Zampieri University of Padova, Department of Medical and Surgical Sciences, Rheumatology Division, Padova, Italy
,
P. Sarzi-Puttini University Hospital L Sacco, Rheumatology Unit, Department of Internal Medicine, Milan, Italy
&
A. Doria University of Padova, Department of Medical and Surgical Sciences, Rheumatology Division, Padova, Italy
 show all
Pages 549-555 | Published online: 07 Jul 2009

Citations (21)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Darosa Lim, Julianne Kleitsch & Victoria P. Werth. (2023) Emerging immunotherapeutic strategies for cutaneous lupus erythematosus: an overview of recent phase 2 and 3 clinical trials. Expert Opinion on Emerging Drugs 0:0, pages 1-17.
Read now
Christopher B Hansen & Jeffrey P Callen. (2015) Current and future treatment options for cutaneous lupus erythematosus. Expert Opinion on Orphan Drugs 3:7, pages 777-786.
Read now

Articles from other publishers (19)

Graciela S. Alarcón, Mario H. Cardiel, Ariel Izcovich, Morton Scheinberg & Bernardo A. Pons-Estel. (2022) A Critical Analysis of the First Latin American Clinical Practice Guidelines for the Treatment of Systemic Lupus Erythematosus. JCR: Journal of Clinical Rheumatology 28:1, pages e312-e316.
Crossref
Jamie Burgess, Maryam Ferdousi, David Gosal, Cheng Boon, Kohei Matsumoto, Anne Marshall, Tony Mak, Andrew Marshall, Bernhard Frank, Rayaz A. Malik & Uazman Alam. (2021) Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment. Oncology and Therapy 9:2, pages 385-450.
Crossref
Josef Symon S. Concha & Victoria P. Werth. 2021. Lahita's Systemic Lupus Erythematosus. Lahita's Systemic Lupus Erythematosus 447 469 .
J.L. Fairley, S. Oon, A.M. Saracino & M. Nikpour. (2020) Management of cutaneous manifestations of lupus erythematosus: A systematic review. Seminars in Arthritis and Rheumatism 50:1, pages 95-127.
Crossref
Sandra Domingo, Cristina Solé, Teresa Moliné, Berta Ferrer, Josep Ordi-Ros & Josefina Cortés-Hernández. (2020) Efficacy of Thalidomide in Discoid Lupus Erythematosus: Insights into the Molecular Mechanisms. Dermatology 236:5, pages 467-476.
Crossref
François Chasset & Camille Francès. (2019) Current Concepts and Future Approaches in the Treatment of Cutaneous Lupus Erythematosus: A Comprehensive Review. Drugs 79:11, pages 1199-1215.
Crossref
François Chasset, Toufik Tounsi, Elise Cesbron, Annick Barbaud, Camille Francès & Laurent Arnaud. (2018) Efficacy and tolerance profile of thalidomide in cutaneous lupus erythematosus: A systematic review and meta-analysis. Journal of the American Academy of Dermatology 78:2, pages 342-350.e4.
Crossref
Tejaswi Kandula, Michelle A. Farrar, Matthew C. Kiernan, Arun V. Krishnan, David Goldstein, Lisa Horvath, Peter Grimison, Frances Boyle, Sally Baron-Hay & Susanna B. Park. (2017) Neurophysiological and clinical outcomes in chemotherapy-induced neuropathy in cancer. Clinical Neurophysiology 128:7, pages 1166-1175.
Crossref
Dandan Wang, Haifeng Chen, Shiying Wang, Yaohong Zou, Jing Li, Jieping Pan, Xiangdang Wang, Tianli Ren, Yu Zhang, Zhiwei Chen, Xuebing Feng & Lingyun Sun. (2016) Thalidomide treatment in cutaneous lesions of systemic lupus erythematosus: a multicenter study in China. Clinical Rheumatology 35:6, pages 1521-1527.
Crossref
Hong-xia Xue, Wen-yi Fu, Hua-dong Cui, Li-li Yang, Ning Zhang & Li-juan Zhao. (2015) High-dose thalidomide increases the risk of peripheral neuropathy in the treatment of ankylosing spondylitis. Neural Regeneration Research 10:5, pages 814.
Crossref
Hillary C. Frankel, Victoria R. Sharon, Ruth Ann Vleugels, Joseph F. Merola & Abrar A. Qureshi. (2013) Lower-dose thalidomide therapy effectively treats cutaneous lupus erythematosus but is limited by neuropathic toxicity. International Journal of Dermatology 52:11, pages 1407-1409.
Crossref
Christopher B. Hansen & Kevin W. Dahle. (2012) Cutaneous lupus erythematosus. Dermatologic Therapy 25:2, pages 99-111.
Crossref
J. Cortés-Hernández, M. Torres-Salido, J. Castro-Marrero, M. Vilardell-Tarres & J. Ordi-Ros. (2012) Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome. British Journal of Dermatology 166:3, pages 616-623.
Crossref
Victoria P. Werth, Cristián Vera Kellet & Jan P. Dutz. 2011. Systemic Lupus Erythematosus. Systemic Lupus Erythematosus 747 768 .
Eduardo Fonseca & Rosa M. Fernández-Torres. 2011. Autoimmune Diseases. Autoimmune Diseases 233 258 .
J. B. Rottman & C. R. Willis. (2010) Mouse Models of Systemic Lupus Erythematosus Reveal a Complex Pathogenesis. Veterinary Pathology 47:4, pages 664-676.
Crossref
R. PlasmatiF. PastorelliM. CavoE. PetracciE. ZamagniP. TosiD. CanginiP. TacchettiF. SalviI. BartolomeiR. MichelucciC. A. Tassinari. (2007) Neuropathy in multiple myeloma treated with thalidomide. Neurology 69:6, pages 573-581.
Crossref
Luca Iaccarino, Mariaelisa Rampudda, Mariagrazia Canova, Sara Della Libera, Piercarlo Sarzi-Puttinic & Andrea Doria. (2007) Mycophenolate mofetil: What is its place in the treatment of autoimmune rheumatic diseases?. Autoimmunity Reviews 6:3, pages 190-195.
Crossref
A Doria, L Iaccarino, S Arienti, ME Rampudda, MG Canova, R Rondinone & S Todesco. (2016) Mycophenolate mofetil and systemic lupus erythematosus. Lupus 15:11_suppl, pages 44-54.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.